title: Discussion on the biologic therapy of inflammatory bowel disease.
authors.forename: M
authors.initials: M
authors.lastname: Merger
authors.forename: H
authors.initials: H
authors.lastname: Herfarth
authors.forename: J
authors.initials: J
authors.lastname: Scholmerich
authors.forename: T
authors.initials: T
authors.lastname: Andus
authors.forename: L
authors.initials: L
authors.lastname: Färber
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000077552:Basiliximab; D001691:Biological Therapy / Q000379:methods*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D015212:Inflammatory Bowel Diseases / Q000628:therapy*; D015375:Receptors, Interleukin-2 / Q000037:antagonists & inhibitors; D011993:Recombinant Fusion Proteins
chemical_list: D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D015375:Receptors, Interleukin-2; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab